Evidence map›Paper›PMID 40198471›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Cerebrospinal-fluid Orexin-A levels in different neurocognitive disorders: a comparison study.

Susana Lozano-Tovar, Riccardo Cremascoli, Marzia Nuccetelli, Giuseppe Sancesario, Stefania Cattaldo, Elisa Prina, Federico Verde, Simone Cappelli, Sergio Bernardini, Nicola Biagio Mercuri and 1 more

Abstract readComparative Study
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Observational
  3. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  4. Review
  5. Reevaluating orexin-a as a biomarker across dementia subtypes: clinical implications and future directions, a letter to editor.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Susana Lozano-TovarFacultad de Psicología, Universidad Nacional Autónoma de México (UNAM), Circuito Ciudad Universitaria Avenida, C.U, Mexico City, 04510, Mexico.
Riccardo CremascoliUnit of Neurology and Neurorehabilitation, IRCCS, Istituto Auxologico Italiano, San Giuseppe Hospital, 28824, Verbania, Italy.
Marzia NuccetelliDepartment of Clinical Biochemistry and Molecular Biology, University of Rome Tor Vergata, Rome, Italy.
Giuseppe SancesarioDepartment of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Stefania CattaldoLaboratory of Clinical Neurobiology, IRCCS, Istituto Auxologico Italiano, San Giuseppe Hospital, 28824, Verbania, Italy.
Elisa PrinaDepartment of Neurology and Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy.
Federico VerdeDepartment of Neurology and Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy.
Simone CappelliLaboratory of Psychology, IRCCS, Istituto Auxologico Italiano, San Giuseppe Hospital, 28824, Verbania, Italy.
Sergio BernardiniUnit of Neurology and Neurorehabilitation, IRCCS, Istituto Auxologico Italiano, San Giuseppe Hospital, 28824, Verbania, Italy.
Nicola Biagio MercuriDepartment of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy.
Claudio LiguoriDepartment of Systems Medicine, University of Rome Tor Vergata, 00133, Rome, Italy. dott.claudioliguori@yahoo.it.ORCID http://orcid.org/0000-0003-2845-1332

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we investigated the differences in cerebrospinal fluid (CSF) orexin-A levels among patients with different neurocognitive disorders, such as mild or moderate to severe Alzheimer's disease (AD; mAD, msAD, respectively), behavioral variants of frontotemporal dementia (bv-FTD), non-fluent primary aphasia (NFPA), and idiopathic normal pressure hydrocephalus (iNPH). A total of 214 participants were evaluated (mAD, 45; msAD, 31; bv-FTD, 12; NFPA, 22; iNPH, 13; non-demented elderly controls, 91). The highest CSF orexin-A levels were found in iNPH patients (263.31 ± 56.89 pg/mL). Patients affected by NFPA (210.86 ± 61.99 pg/mL), iNPH, and msAD (173.04 ± 19.76 pg/mL) showed higher CSF orexin-A concentrations than controls (145.18 ± 27.01pg/mL) (p < 0.001). Bv-FTD (190.12 ± 100.84 pg/mL) and mAD (130.76 ± 21.70 pg/mL) patients showed no significant differences in CSF orexin-A levels compared with controls. mAD patients showed also lower CSF orexin-A concentrations than all other patient groups.In conclusion, orexin-A presents different CSF levels among neurocognitive disorders. The mechanisms underlying this difference vary and may include sleep-wake cycle impairment, behavioral disturbances, and CSF dynamics. The development of drugs that antagonize the orexin system could open a new frontier of research linking orexin neurotransmission to neurocognitive disorders.

Indexed as

Neurocognitive DisordersOrexinsAgedAged, 80 and overFemaleHumansMaleMiddle AgedOrexinsAlzheimer’s diseaseCognitive impairmentDementiaFTDiNPHOrexin-Atauβ-amyloid

Identifiers

PMID40198471
PMCPMC12267319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.